ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?

Clin Cancer Res. 2019 Nov 15;25(22):6561-6563. doi: 10.1158/1078-0432.CCR-19-2270. Epub 2019 Sep 20.

Abstract

BCR-ABL1 transcripts at imatinib cessation were quantified by droplet digital PCR (ddPCR) for 175 patients on the STIM2 trial. Patients with BCR-ABL1 transcripts below a defined cutoff had a 12-month molecular recurrence rate of 46% versus 68% for those above the cutoff. Implications of using ddPCR in forecasting successful imatinib cessation are discussed.See related article by Nicolini et al., p. 6606.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Neoplasm Recurrence, Local
  • Polymerase Chain Reaction

Substances

  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl